Autoimmune Hepatitis Association, 704 SR-135 S, STE D, Box 183, Greenwood, IN (2025)

11/27/2025

🍂🦃 Happy Thanksgiving from the Autoimmune Hepatitis Association! 🦃🍂

As we gather with loved ones and reflect on the past year, the AIHA is incredibly grateful for you — our community of patients, caregivers, medical professionals, advocates, and supporters.

Your courage, your voices, your willingness to share your stories, and your commitment to helping others living with autoimmune hepatitis make our mission possible every single day.

This year, we’re thankful for:

🌟 The strength of our patient community, who continue to show resilience and hope through every step of their journey.

🌟 Dedicated caregivers, whose compassion and support make a world of difference.

🌟 Healthcare providers and researchers, advancing understanding, improving treatments, and offering life-changing care.

🌟 Our AIHA volunteers, who raise awareness and ensure no one faces AIH alone.

🌟 The progress we’ve made together, from shared education to growing resources to the connections built across the country and around the world.

Today, and every day, we are grateful for this community — for your trust, your stories, your strength, and your heart.

Wishing you all a warm, restful, and meaningful Thanksgiving.
May your day be filled with comfort, connection, and gratitude. 🧡

What are you thankful for this year? Share in the comments — we’d love to celebrate with you! 🍁

11/12/2025

That’s a wrap on The Liver Meeting® 2025!
Grateful for all the inspiring discussions and connections made this weekend. 💜

Here’s to continued collaboration and progress for everyone impacted by autoimmune hepatitis!

11/11/2025

The Best of The Liver Meeting® 2025: Research in Autoimmune Hepatitis

💊 Steroid Use Still Common — and Risky — in Autoimmune Hepatitis (AIH)

Corticosteroids (CS), or “steroids,” are often used to treat autoimmune hepatitis (AIH). These medicines help control liver inflammation, but long-term steroid use can cause serious side effects — even at low doses.

A new study led by Indiana University and the Autoimmune Hepatitis Association looked at how often people with AIH use steroids and what side effects they experience.

🔬 What the study found:

Among 592 AIH patients from around the world, 37% were currently taking steroids, even though they were taking other “steroid-sparing” treatments and had an average disease duration of 6 years.
🔹A history of long-term steroid use (more than 90 days a year) was reported by 68% of patients and was linked to osteoporosis and high blood pressure.

🔹Concerningly, nearly half of AIH patients treated with steroids at diagnosis reported new medical issues within 6 months of diagnosis — most commonly weight gain, high blood pressure, and diabetes.

💡 Why this matters for patients:

This study shows that steroids are still widely used in AIH even years after diagnosis, despite their risks. Many patients face lasting side effects from long-term use. These results highlight the urgent need for safer, steroid-sparing treatment options — and for continued research to improve care for people living with autoimmune hepatitis.

11/10/2025

⭐We’re live from The Liver Meeting® 2025! New Research alert!

💊A New Study Looks at Safer Options for Autoimmune Hepatitis (AIH) Treatment
A new study by German researchers examined two other medicines commonly used in AIH, 6-mercaptopurine (6-MP) and mycophenolate mofetil (MMF), to determine which works better and is easier to tolerate when AZA can’t be used.
Many people with autoimmune hepatitis (AIH) take medicines called azathioprine (AZA) and corticosteroids. But about 1 in 4 patients have to stop AZA because of side effects.

A new study by researchers in Germany looked at two other medicines that are commonly used in AIH, 6-mercaptopurine (6-MP) and mycophenolate mofetil (MMF), to see which works better and is easier to tolerate when AZA can’t be used.

Both 6-MP and MMF worked about the same in controlling liver inflammation.

Researchers followed 211 patients with AIH who could not tolerate AZA.
Both 6-MP and MMF worked about the same at controlling liver inflammation.
However, MMF caused fewer side effects — patients were able to stay on MMF 89% of the time compared to 67% for 6-MP.

6-MP might still be a good option for women of childbearing age, since it’s safer during pregnancy and doctors can track drug levels more closely.

💡 Why does this matter for patients?

This study gives doctors and patients better information when AZA isn’t an option. Both 6-MP and MMF can help keep AIH under control, and patients can work with their care team to find the treatment that best fits their needs and lifestyle.

11/09/2025

The Best of The Liver Meeting® 2025: New Research in Autoimmune Hepatitis

Each year, liver doctors and scientists from around the world come together for The Liver Meeting® to share the newest research about liver diseases — including autoimmune hepatitis (AIH). It’s one of the most exciting events for liver health, bringing together ideas that can help improve care and treatment for patients.

Our Executive Director and hepatologist, Dr. Craig Lammert, has summarized one of the most important new abstracts related to autoimmune hepatitis.

One study asked an important question: Does long-term prednisone use increase the risk of liver cancer in people with autoimmune hepatitis and cirrhosis?

For decades, prednisone has been a key medication for treating autoimmune hepatitis. It helps calm the immune system and protect the liver from inflammation. But doctors and patients know that prednisone can also bring unwanted side effects when used for long periods — like weight gain, diabetes, and bone loss.

Researchers wanted to explore whether long-term prednisone use could also increase the risk of hepatocellular carcinoma (HCC), a type of liver cancer, in people who already have cirrhosis (scarring of the liver).

The study included 121 adults with autoimmune hepatitis and cirrhosis who were treated between 2001 and 2023.

Participants were divided into two groups:
-High prednisone exposure: People who took more than 7.5 mg per day for at least six months after being diagnosed with cirrhosis.
-Low or no prednisone exposure: People who took less than 7.5 mg per day or were managed with other treatments.

Researchers then looked at how many patients in each group developed liver cancer over time.

The results were striking. Liver cancer developed in about 25% of people in the high prednisone group, compared to about 10% in the lower-use group.
The yearly rate of liver cancer was 3.3% for those taking higher doses of prednisone, compared to 0.9% for those taking less.

Even after adjusting for age, gender, ethnicity, and liver disease severity, prednisone use remained an independent risk factor for developing liver cancer.
The authors suggested that prednisone’s long-term effects on the immune system and metabolism may reduce the liver’s ability to “watch for” and fight off abnormal cells — potentially raising the risk of cancer in people with cirrhosis.

This study doesn’t mean people should stop taking prednisone — it’s still a lifesaving treatment that remains essential for many. Instead, it highlights the importance of personalized care and regular follow-up with your liver specialist. Doctors may look for ways to use the lowest effective dose of prednisone or explore steroid-sparing options that control liver inflammation while lowering long-term risks.

Prednisone continues to play an important role in autoimmune hepatitis treatment. But as this study shows, it’s equally important to understand its long-term effects, especially for people living with cirrhosis.

By studying these patterns, researchers hope to find better, safer ways to manage autoimmune hepatitis — and help patients live longer, healthier lives.

11/08/2025

📍 We’re live from The Liver Meeting® 2025 — surrounded by more than 9,000 scientists, doctors, and researchers, all focused on liver disease.

Now, we want to bring YOU, our Autoimmune Hepatitis (AIH) community, right here to the booth with us. 💬💪

Imagine you’re standing here with the Autoimmune Hepatitis Association team — surrounded by the world’s leading liver experts. What would you tell them?

👉 What do you most want them to understand about living with AIH?
👉 What are the three biggest needs or priorities you’d ask them to focus on for our disease?
👉 What part of your AIH story do you wish they could hear directly from you?

Share your thoughts below. ⬇️

We’ll bring your voices to the Exhibit Hall at TLM. Your insights, hopes, and challenges deserve to be heard by those shaping the future of AIH research and care.

11/08/2025

💜 Best of The Liver Meeting: A New Antibody Discovery in Autoimmune Hepatitis

One of the exciting new studies shared at this year’s Liver Meeting looked for better blood tests to help doctors diagnose autoimmune hepatitis (AIH).

Right now, doctors often check for certain autoantibodies like ANA or ASMA, but these aren’t specific to AIH — meaning they can show up in other diseases too. That can make diagnosis tricky.

🧪 What the researchers did:

Scientists studied blood from people with AIH and from healthy volunteers. They looked at more than 16,000 different human proteins to see if any unique antibodies showed up only in people with AIH.

They discovered that patients with AIH often had higher levels of a new antibody — called anti-DOK2. This antibody was found in people with AIH but not in most people with other liver diseases or in healthy controls.

The researchers also found that higher levels of anti-DOK2 were linked to:

-Higher IgG levels (a sign of immune system activity)
-More active inflammation in the liver

💡 What this means for patients:

This study is the first to identify anti-DOK2 antibodies as a possible marker for autoimmune hepatitis (AIH). If future research confirms these findings, this test might help:
-Diagnose AIH more accurately
-Monitor disease activity or response to treatment
-Improve our understanding of what causes AIH

Right now, doctors often check for certain autoantibodies, like ANA or ASMA, but these aren’t specific to AIH — meaning they can also show up in other diseases. That can make diagnosis tricky.

While it’s still early, this discovery gives hope that better and more specific tests for AIH could be on the way — helping patients and doctors get answers faster.

11/07/2025

📢 Big News from the Autoimmune Hepatitis Association!

We are excited to announce that we will be attending The Liver Meeting® 2025 (hosted by the American Association for the Study of Liver Diseases, or AASLD) from November 7-11, 2025 in Washington, D.C.

What is The Liver Meeting?

This annual conference brings together doctors, researchers, scientists, and advocates from around the world who focus on liver health.

What is at The Liver Meeting?

🟣Presentations of the newest research on liver diseases (via posters and oral talks)
🟣Education sessions where people learn about treatments, guidelines, and how to improve care
🟣Networking time where hepatologists (liver doctors), researchers, industry partners, and patient‐advocates meet to share ideas

Why does this matter for patients with autoimmune hepatitis?

This meeting helps move liver disease science forward, and it also impacts what we do to support you.

Why does the AIHA have a booth at the conference?

🟣Share with doctors, researchers, and industry partners what we do: patient education, research, advocacy
🟣Meet and engage with the liver‐disease community so that autoimmune hepatitis is part of the discussion
🟣Learn about the very latest science that may help improve care, outcomes, and information for patients

What can the AIH community expect from the AIHA?

Keep an eye on our social media pages while we are there — we’ll post updates, insights from the conference, and share how the meeting may connect to autoimmune hepatitis. We are looking forward to keeping you in the loop. Thanks to our community of patients, advocates, and caregivers — you are why we’re here.

— The Autoimmune Hepatitis Association

11/06/2025

🌟 New Blog Post Alert 🌟

“Is Autoimmune Hepatitis a Rare Disease?”

Living with Autoimmune Hepatitis (AIH) often leads to big questions: How common is this condition? What does “rare disease” really mean? In our latest blog, we explore these questions.

💬 Why this matters:
Understanding how common (or uncommon) AIH is can help reduce isolation and empower those living with the condition. When we know more, we connect better — and we advocate stronger.

🔗 Dive into the full blog for the detailed breakdown and join the conversation. → https://aihep.org/post/is-autoimmune-hepatitis-a-rare-disease/

11/05/2025

Please join in the next virtual AIH Support Group Meeting for Men, which will be held on Thursday, November 6 from 7:00 to 8:30 p.m. ET on Zoom. This group will be led by a volunteer who is a male patient. Please email info@aihep.org to receive the meeting link.
----------------------------
𝘚𝘶𝘱𝘱𝘰𝘳𝘵 𝘨𝘳𝘰𝘶𝘱𝘴 𝘥𝘰 𝘯𝘰𝘵 𝘩𝘢𝘷𝘦 𝘢 𝘣𝘶𝘴𝘪𝘯𝘦𝘴𝘴 𝘳𝘦𝘭𝘢𝘵𝘪𝘰𝘯𝘴𝘩𝘪𝘱 𝘸𝘪𝘵𝘩 𝘵𝘩𝘦 𝘈𝘶𝘵𝘰𝘪𝘮𝘮𝘶𝘯𝘦 𝘏𝘦𝘱𝘢𝘵𝘪𝘵𝘪𝘴 𝘈𝘴𝘴𝘰𝘤𝘪𝘢𝘵𝘪𝘰𝘯 (𝘈𝘐𝘏𝘈) 𝘯𝘰𝘳 𝘢𝘳𝘦 𝘵𝘩𝘦𝘺 𝘢𝘨𝘦𝘯𝘵𝘴 𝘵𝘩𝘦𝘳𝘦𝘰𝘧 𝘰𝘳 𝘦𝘯𝘥𝘰𝘳𝘴𝘦𝘥 𝘦𝘹𝘱𝘭𝘪𝘤𝘪𝘵𝘭𝘺 𝘣𝘺 𝘵𝘩𝘦 𝘈𝘐𝘏𝘈. 𝘛𝘩𝘦 𝘈𝘐𝘏𝘈 𝘢𝘤𝘤𝘦𝘱𝘵𝘴 𝘯𝘰 𝘳𝘦𝘴𝘱𝘰𝘯𝘴𝘪𝘣𝘪𝘭𝘪𝘵𝘺 𝘧𝘰𝘳 𝘢𝘯𝘺 𝘭𝘪𝘢𝘣𝘪𝘭𝘪𝘵𝘺, 𝘤𝘰𝘴𝘵𝘴, 𝘰𝘳 𝘦𝘯𝘤𝘶𝘮𝘣𝘳𝘢𝘯𝘤𝘦 𝘪𝘯𝘤𝘶𝘳𝘳𝘦𝘥 𝘣𝘺 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘨𝘳𝘰𝘶𝘱𝘴. 𝘚𝘶𝘱𝘱𝘰𝘳𝘵 𝘨𝘳𝘰𝘶𝘱𝘴, 𝘸𝘩𝘪𝘭𝘦 𝘯𝘰𝘵 𝘢𝘧𝘧𝘪𝘭𝘪𝘢𝘵𝘦𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘈𝘐𝘏𝘈, 𝘴𝘩𝘰𝘶𝘭𝘥 𝘴𝘵𝘪𝘭𝘭 𝘣𝘦 𝘮𝘪𝘯𝘥𝘧𝘶𝘭 𝘵𝘩𝘢𝘵 𝘢𝘯𝘺 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯 𝘰𝘳 𝘨𝘦𝘯𝘦𝘳𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘥 𝘵𝘰 𝘮𝘦𝘮𝘣𝘦𝘳𝘴 𝘥𝘰𝘦𝘴 𝘯𝘰𝘵 𝘤𝘰𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘦 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘰𝘳 𝘭𝘦𝘨𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦 𝘢𝘯𝘥 𝘴𝘶𝘤𝘩 𝘪𝘯𝘱𝘶𝘵 𝘴𝘩𝘰𝘶𝘭𝘥 𝘢𝘭𝘸𝘢𝘺𝘴 𝘣𝘦 𝘴𝘰𝘭𝘪𝘤𝘪𝘵𝘦𝘥 𝘧𝘳𝘰𝘮 𝘱𝘳𝘰𝘧𝘦𝘴𝘴𝘪𝘰𝘯𝘢𝘭𝘴.

11/05/2025

The Southeast AIH Support Group will hold its next virtual meeting at 7 p.m. ET on Thursday, November 6. New members are always welcome to attend!

Email info@aihep.org to receive the Zoom link. We hope you can attend!
------
𝘚𝘶𝘱𝘱𝘰𝘳𝘵 𝘨𝘳𝘰𝘶𝘱𝘴 𝘥𝘰 𝘯𝘰𝘵 𝘩𝘢𝘷𝘦 𝘢 𝘣𝘶𝘴𝘪𝘯𝘦𝘴𝘴 𝘳𝘦𝘭𝘢𝘵𝘪𝘰𝘯𝘴𝘩𝘪𝘱 𝘸𝘪𝘵𝘩 𝘵𝘩𝘦 𝘈𝘶𝘵𝘰𝘪𝘮𝘮𝘶𝘯𝘦 𝘏𝘦𝘱𝘢𝘵𝘪𝘵𝘪𝘴 𝘈𝘴𝘴𝘰𝘤𝘪𝘢𝘵𝘪𝘰𝘯 (𝘈𝘐𝘏𝘈) 𝘯𝘰𝘳 𝘢𝘳𝘦 𝘵𝘩𝘦𝘺 𝘢𝘨𝘦𝘯𝘵𝘴 𝘵𝘩𝘦𝘳𝘦𝘰𝘧 𝘰𝘳 𝘦𝘯𝘥𝘰𝘳𝘴𝘦𝘥 𝘦𝘹𝘱𝘭𝘪𝘤𝘪𝘵𝘭𝘺 𝘣𝘺 𝘵𝘩𝘦 𝘈𝘐𝘏𝘈. 𝘛𝘩𝘦 𝘈𝘐𝘏𝘈 𝘢𝘤𝘤𝘦𝘱𝘵𝘴 𝘯𝘰 𝘳𝘦𝘴𝘱𝘰𝘯𝘴𝘪𝘣𝘪𝘭𝘪𝘵𝘺 𝘧𝘰𝘳 𝘢𝘯𝘺 𝘭𝘪𝘢𝘣𝘪𝘭𝘪𝘵𝘺, 𝘤𝘰𝘴𝘵𝘴, 𝘰𝘳 𝘦𝘯𝘤𝘶𝘮𝘣𝘳𝘢𝘯𝘤𝘦 𝘪𝘯𝘤𝘶𝘳𝘳𝘦𝘥 𝘣𝘺 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘨𝘳𝘰𝘶𝘱𝘴. 𝘚𝘶𝘱𝘱𝘰𝘳𝘵 𝘨𝘳𝘰𝘶𝘱𝘴, 𝘸𝘩𝘪𝘭𝘦 𝘯𝘰𝘵 𝘢𝘧𝘧𝘪𝘭𝘪𝘢𝘵𝘦𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘈𝘐𝘏𝘈, 𝘴𝘩𝘰𝘶𝘭𝘥 𝘴𝘵𝘪𝘭𝘭 𝘣𝘦 𝘮𝘪𝘯𝘥𝘧𝘶𝘭 𝘵𝘩𝘢𝘵 𝘢𝘯𝘺 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯 𝘰𝘳 𝘨𝘦𝘯𝘦𝘳𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘥 𝘵𝘰 𝘮𝘦𝘮𝘣𝘦𝘳𝘴 𝘥𝘰𝘦𝘴 𝘯𝘰𝘵 𝘤𝘰𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘦 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘰𝘳 𝘭𝘦𝘨𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦 𝘢𝘯𝘥 𝘴𝘶𝘤𝘩 𝘪𝘯𝘱𝘶𝘵 𝘴𝘩𝘰𝘶𝘭𝘥 𝘢𝘭𝘸𝘢𝘺𝘴 𝘣𝘦 𝘴𝘰𝘭𝘪𝘤𝘪𝘵𝘦𝘥 𝘧𝘳𝘰𝘮 𝘱𝘳𝘰𝘧𝘦𝘴𝘴𝘪𝘰𝘯𝘢𝘭𝘴.

11/02/2025

📢 Attention Young Adult AIH Support Group members!

We have some important updates regarding our meeting schedule for November and December. Our next meetings will be held on:

⭐ Monday, November 3 from 7:00 p.m. to 8:00 p.m. ET
⭐Monday, December 1 from 7:00 p.m. to 8:00 p.m. ET

We appreciate your understanding and flexibility. We will resume our regular meetings on the first Tuesday of the month, starting in January. We look forward to seeing you there! 💙

This group is designed to allow young adult patients between the ages of 18 and 40 to connect with one another, share their experiences with the disease, and provide (and receive) support!

Email info@aihep.org to receive the Zoom link.

-----------------------------------------------
𝘚𝘶𝘱𝘱𝘰𝘳𝘵 𝘨𝘳𝘰𝘶𝘱𝘴 𝘥𝘰 𝘯𝘰𝘵 𝘩𝘢𝘷𝘦 𝘢 𝘣𝘶𝘴𝘪𝘯𝘦𝘴𝘴 𝘳𝘦𝘭𝘢𝘵𝘪𝘰𝘯𝘴𝘩𝘪𝘱 𝘸𝘪𝘵𝘩 𝘵𝘩𝘦 𝘈𝘶𝘵𝘰𝘪𝘮𝘮𝘶𝘯𝘦 𝘏𝘦𝘱𝘢𝘵𝘪𝘵𝘪𝘴 𝘈𝘴𝘴𝘰𝘤𝘪𝘢𝘵𝘪𝘰𝘯 (𝘈𝘐𝘏𝘈) 𝘯𝘰𝘳 𝘢𝘳𝘦 𝘵𝘩𝘦𝘺 𝘢𝘨𝘦𝘯𝘵𝘴 𝘵𝘩𝘦𝘳𝘦𝘰𝘧 𝘰𝘳 𝘦𝘯𝘥𝘰𝘳𝘴𝘦𝘥 𝘦𝘹𝘱𝘭𝘪𝘤𝘪𝘵𝘭𝘺 𝘣𝘺 𝘵𝘩𝘦 𝘈𝘐𝘏𝘈. 𝘛𝘩𝘦 𝘈𝘐𝘏𝘈 𝘢𝘤𝘤𝘦𝘱𝘵𝘴 𝘯𝘰 𝘳𝘦𝘴𝘱𝘰𝘯𝘴𝘪𝘣𝘪𝘭𝘪𝘵𝘺 𝘧𝘰𝘳 𝘢𝘯𝘺 𝘭𝘪𝘢𝘣𝘪𝘭𝘪𝘵𝘺, 𝘤𝘰𝘴𝘵𝘴, 𝘰𝘳 𝘦𝘯𝘤𝘶𝘮𝘣𝘳𝘢𝘯𝘤𝘦 𝘪𝘯𝘤𝘶𝘳𝘳𝘦𝘥 𝘣𝘺 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘨𝘳𝘰𝘶𝘱𝘴. 𝘚𝘶𝘱𝘱𝘰𝘳𝘵 𝘨𝘳𝘰𝘶𝘱𝘴, 𝘸𝘩𝘪𝘭𝘦 𝘯𝘰𝘵 𝘢𝘧𝘧𝘪𝘭𝘪𝘢𝘵𝘦𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘈𝘐𝘏𝘈, 𝘴𝘩𝘰𝘶𝘭𝘥 𝘴𝘵𝘪𝘭𝘭 𝘣𝘦 𝘮𝘪𝘯𝘥𝘧𝘶𝘭 𝘵𝘩𝘢𝘵 𝘢𝘯𝘺 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯 𝘰𝘳 𝘨𝘦𝘯𝘦𝘳𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘥 𝘵𝘰 𝘮𝘦𝘮𝘣𝘦𝘳𝘴 𝘥𝘰𝘦𝘴 𝘯𝘰𝘵 𝘤𝘰𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘦 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘰𝘳 𝘭𝘦𝘨𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦 𝘢𝘯𝘥 𝘴𝘶𝘤𝘩 𝘪𝘯𝘱𝘶𝘵 𝘴𝘩𝘰𝘶𝘭𝘥 𝘢𝘭𝘸𝘢𝘺𝘴 𝘣𝘦 𝘴𝘰𝘭𝘪𝘤𝘪𝘵𝘦𝘥 𝘧𝘳𝘰𝘮 𝘱𝘳𝘰𝘧𝘦𝘴𝘴𝘪𝘰𝘯𝘢𝘭𝘴.

Autoimmune Hepatitis Association

11/27/2025

11/12/2025

11/11/2025

11/10/2025

11/09/2025

11/08/2025

11/08/2025

11/07/2025

11/06/2025

11/05/2025

11/05/2025

11/02/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category